Trial failure may signal the end for gamma secretase blockers

07/25/2013 | HealthDay News

Cognitive ability of clinical trial participants with mild to moderate Alzheimer's disease declined faster in the group taking gamma secretase-blocker semagacestat than in the placebo group, researchers report in The New England Journal of Medicine. The drug, designed to block an enzyme that makes beta amyloid plaques in the brain, worked as designed in early human and animal trials but failed to improve thinking skills in this trial.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC